Updated:
Kairos Pharma
Kairos Pharma is a development-stage biopharmaceutical firm targeting drug resistance in cancer, filing for a public listing in 2021.
Kairos Pharma
Kairos Pharma, LTD. is a pre-revenue, development-stage biopharmaceutical company focused on oncology. The company emerged publicly in 2021 when it filed an S-1 registration statement with the U.S. Securities and Exchange Commission, signaling an intention to raise public capital via an initial public offering (per SEC filing, 2021). The company's lead therapeutic candidate, KROS-101, is designed to target key mechanisms of drug resistance in cancer cells. Public filings describe a strategy centered on acquiring and developing novel small-molecule and biologic compounds that address pathways tumors use to evade standard-of-care treatments. At the time of its SEC filing, the company had not yet generated revenue and planned to deploy raised capital into clinical trials, manufacturing scale-up, and a targeted Phase 2 study. Headquartered in Los Angeles and structured under a Bermuda parent entity, Kairos Pharma operated with a lean research team led by CEO John Yu at its registration. The company indicated in public records that its initial clinical focus targets glioblastoma and other solid tumors. No post-filing public offering completion or subsequent private financing round has been officially disclosed as of mid-2026. Unlike venture-backed biotechs that remain private through Phase 1 data, Kairos Pharma sought a direct public listing at a pre-clinical or early clinical stage — an unusual capital structure that bypasses traditional crossover rounds and exposes the development pipeline to public market scrutiny from the outset.
General information
Firm type
Unclassified
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is Kairos Pharma's lead therapeutic candidate?
Kairos Pharma's lead candidate is KROS-101, a molecule designed to interfere with the biological pathways tumors use to develop resistance to conventional cancer therapies. Public filings from the company's 2021 S-1 registration identified glioblastoma as an initial clinical target, with additional solid-tumor indications under consideration.
Is Kairos Pharma publicly traded or still private?
Kairos Pharma filed an S-1 registration statement with the SEC in 2021 seeking a public listing on the NYSE American under the ticker 'KPRX,' with a proposed maximum offering of $17.25 million. As of mid-2026, no trading data or completed-IPO announcement has been confirmed in public records, leaving the company's current status unresolved.
Who runs investment decisions at Kairos Pharma?
As a development-stage operating company rather than an investment firm, Kairos Pharma does not have traditional allocators — strategic decisions are made by management and the board. Dr. John Yu was listed as Chief Executive Officer and a director in the company's 2021 SEC filing, with scientific direction overseen by a small team of oncology researchers.
What is the structural significance of Kairos Pharma filing for an IPO at this stage?
Most biotech firms at the pre-clinical or Phase 1 stage remain privately funded by venture capital syndicates. Kairos Pharma's 2021 S-1 filing represents a minority posture: seeking public market capital before clinical validation, which signals either limited access to traditional venture rounds or a deliberate choice to tap retail and institutional public investors early.
Does Kairos Pharma have a family office or pooled investment vehicle structure?
No. Kairos Pharma is structured as a biopharmaceutical operating company incorporated in Bermuda, according to its public filings. There is no indication it functions as, or is affiliated with, a family office, multi-family office, or private investment fund.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: